A Phase 1 Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants with Gastrointestinal Malignancies

Brief description of study

The purpose of this study is to understand whether potential new drugs, AB680 and AB122, can be safely given to patients with pancreatic cancer in combination with Gemcitabine and Nab-paclitaxel chemotherapy and to assess the safety and tolerability of AB680 in combination with AB122 and standard chemotherapy. Additionally, the study will look at the amount of study drugs in the blood to evaluate the way the body processes the study drugs (pharmacokinetics) and the way the study drugs affect your body (pharmacodynamics). The study will also look at your immune response to the study drugs.AB680 and AB122 (the study drugs) are “investigational”, which means they are not approved by the United States Food and Drug Administration (U.S. FDA).


Clinical Study Identifier: s19-01021
ClinicalTrials.gov Identifier: NCT04104672
Principal Investigator: Paul E. Oberstein.
Other Investigators: Shun Yu, Nina Beri, Kristen Spencer, Daniel J Becker, Jennifer Chuy.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.